JAAD meta-analysis weighs Pneumocystis prophylaxis in rituximab patients

A systematic review and meta-analysis published in the Journal of the American Academy of Dermatology, Volume 95, Issue 5, dated November 2026, examines whether primary prophylaxis prevents Pneumocystis pneumonia in patients receiving rituximab for immune-mediated dermatologic conditions.

The study, led by Stephanie Y. Zhang with co-authors Julia Gex, Katy Austin, Sai Sarnala, Catherine Seelig, Youngeun Elli Lee, Thomas Y. Li and Vicky Ren, consolidates the available evidence on a prophylaxis question that dermatologists face whenever they prescribe rituximab. The drug anchors treatment for several immune-mediated skin diseases, including pemphigus vulgaris and other blistering disorders, and infectious risk has long sat alongside its efficacy.

Rituximab depletes B cells for months after each course. That prolonged immunosuppression creates the theoretical ground for Pneumocystis jirovecii pneumonia, an opportunistic infection with meaningful mortality. Whether dermatology patients on rituximab carry enough risk to justify routine primary prophylaxis — typically with trimethoprim-sulfamethoxazole — has remained unsettled, and practice varies widely across centers.

What does the review cover?

The authors pooled data from studies of patients treated with rituximab for dermatologic indications, comparing outcomes between those who received primary prophylaxis and those who did not. The design is a systematic review with meta-analysis, the highest evidence class short of a randomized trial, and it directly targets the dermatology cohort rather than extrapolating from rheumatology, oncology or transplant literature where most prior guidance originated.

That distinction matters. Rheumatology societies recommend prophylaxis for some rituximab regimens, but dermatologic dosing schedules, concurrent steroid exposure and baseline immune profiles differ. Guidance borrowed from other specialties has never been validated in skin-disease populations.

Why the question matters now

Rituximab use in dermatology has expanded as clinicians increasingly turn to it for refractory autoimmune blistering disease and other immune-mediated conditions. Each new prescriber inherits the same unresolved decision: prescribe prophylaxis for every patient, or reserve it for those with additional risk factors such as high-dose concomitant glucocorticoids, lymphopenia or older age.

Prophylaxis itself carries cost. Trimethoprim-sulfamethoxazole can cause rash, cytopenias and, rarely, severe hypersensitivity, so an evidence-based threshold matters as much for avoiding unnecessary treatment as for preventing infection.

What clinicians should watch for

The full analysis, including the pooled infection rates and the strength of the prophylaxis signal, appears in JAAD's November 2026 issue. Dermatologists who prescribe rituximab will want to weigh the pooled estimates against their own patients' comorbidity profiles and concomitant immunosuppression.

If the meta-analysis confirms a meaningful protective effect, it could push specialty societies toward explicit prophylaxis recommendations for dermatologic rituximab protocols. If the absolute risk proves low, the findings may spare many patients unnecessary medication — either way, the November 2026 issue gives the specialty its first aggregated answer to a question it has managed on institutional habit for years.